Recent Analysts’ Ratings Updates for Astrazeneca (AZN)

Several brokerages have updated their recommendations and price targets on shares of Astrazeneca (NYSE: AZN) in the last few weeks:

• 5/21/2026 – Astrazeneca had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 5/14/2026 – Astrazeneca had its “buy” rating reaffirmed by JPMorgan Chase & Co..
• 5/13/2026 – Astrazeneca had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 5/4/2026 – Astrazeneca had its “buy” rating reaffirmed by Sanford C. Bernstein.
• 5/2/2026 – Astrazeneca was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/30/2026 – Astrazeneca had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 4/30/2026 – Astrazeneca had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 4/29/2026 – Astrazeneca was upgraded by Barclays PLC from “neutral” to “buy”.
• 4/29/2026 – Astrazeneca was upgraded by DZ Bank AG from “neutral” to “buy”.
• 4/23/2026 – Astrazeneca had its “buy” rating reaffirmed by JPMorgan Chase & Co..
• 4/10/2026 – Astrazeneca had its “buy” rating reaffirmed by UBS Group AG.
• 4/8/2026 – Astrazeneca had its “overweight” rating reaffirmed by Morgan Stanley.
• 4/4/2026 – Astrazeneca was downgraded by Wall Street Zen from “buy” to “hold”.

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.